Skip to main content

Robert G. Kidwell

  • Co-lead trial counsel in the 2020 jury trial of a nationwide class action alleging global price fixing in sales of capacitors.
  • Lead U.S. antitrust counsel for Qiagen N.V. in its $11 billion sale to Thermo Fisher Scientific, announced in March 2020.
  • Successfully represented a global contract manufacturer before the Committee on Foreign Investment in the United States (CFIUS) in its 2020 acquisition by a Chinese investor.
  • Serves as ongoing antitrust counsel to one of the nation’s largest and most respected integrated physician/hospital provider network on matters including mergers, affiliations, investigations, and litigation.
  • Represented the nation’s premier retail pharmacy chain in its $27 billion industry-transforming acquisition of a “big three” pharmacy benefits manager.
  • Serves as ongoing antitrust counsel to several of the world’s leading genetic and molecular diagnostic test developers and providers.
  • Lead counsel for three separate cable operators in sprawling multidistrict litigation involving more than 30 separate suits filed around the country relating to the alleged tying of cable set-top boxes to certain cable services.
  • Serves as ongoing antitrust counsel to one of the world’s largest and most recognizable brands in healthcare equipment and technology.
  • Serves as ongoing antitrust, regulatory, and litigation counsel to several of the nation’s leading cable, media, and wireless telecommunications companies and trade associations.
  • Provides ongoing antitrust and foreign investment counsel to dozens of early-stage companies in biotech, healthcare, green energy, and high-tech manufacturing.
Case Study
Mintz is leading a NYSE company’s defense in US criminal price-fixing cartel investigations and a US class action with nearly two dozen codefendants. Mintz is also coordinating with non-US counsel on related foreign actions regarding the alleged international cartel.
Case Study
Mintz guided a Fortune 50 corporation through a joint investigation by the Federal Trade Commission’s Bureau of Competition and Bureau of Consumer Protection that included civil investigative demands and hearings. The corporation’s merger was preserved, and none of its actions was challenged.
Case Study
Mintz led a heavily negotiated settlement that enabled a large health care system to acquire a hospital and physician group. The joint Department of Justice, state Attorney General, and state agency investigation included a “second request” in accordance with the Hart-Scott-Rodino (HSR) Act.